Adell Harriman & Carpenter Inc Gilead Sciences, Inc. Transaction History

Adell Harriman & Carpenter Inc

$1.38 Trillion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$71.58 - $87.29 $86,826 - $105,882	-1,213 Reduced 20.24%	4,780 $350 Million
Q4 2023 Feb 05, 2024	SELL	$73.27 - $83.09 $95,251 - $108,017	-1,300 Reduced 17.83%	5,993 $485 Million
Q3 2023 Nov 07, 2023	SELL	$73.94 - $80.67 $14,788 - $16,134	-200 Reduced 2.67%	7,293 $547 Million
Q2 2023 Aug 04, 2023	SELL	$76.01 - $86.7 $1,900 - $2,167	-25 Reduced 0.33%	7,493 $575 Million
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $773 - $880	-10 Reduced 0.13%	7,518 $624 Million
Q4 2022 Feb 03, 2023	BUY	$62.32 - $89.47 $81,016 - $116,311	1,300 Added 20.87%	7,528 $646 Million
Q3 2022 Nov 03, 2022	BUY	$59.54 - $68.01 $11,908 - $13,602	200 Added 3.32%	6,228 $384 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $18,585 - $20,933	322 Added 5.64%	6,028 $372,000
Q1 2022 Apr 29, 2022	SELL	$57.92 - $72.58 $191,136 - $239,514	-3,300 Reduced 36.64%	5,706 $339,000
Q4 2021 Feb 16, 2022	BUY	$64.88 - $73.64 $4,217 - $4,786	65 Added 0.73%	9,006 $653,000
Q3 2021 Nov 05, 2021	BUY	$67.69 - $73.03 $54,152 - $58,424	800 Added 9.83%	8,941 $624,000
Q2 2021 Aug 10, 2021	BUY	$63.47 - $69.35 $6,347 - $6,934	100 Added 1.24%	8,141 $560,000
Q1 2021 May 03, 2021	BUY	$60.0 - $68.46 $222,000 - $253,301	3,700 Added 85.23%	8,041 $519,000
Q4 2020 Feb 05, 2021	BUY	$56.65 - $64.55 $22,660 - $25,820	400 Added 10.15%	4,341 $252,000
Q3 2020 Nov 06, 2020	SELL	$62.1 - $78.08 $21,735 - $27,328	-350 Reduced 8.16%	3,941 $249,000
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $53,169 - $61,740	-735 Reduced 14.62%	4,291 $330,000
Q1 2020 May 07, 2020	BUY	$62.63 - $80.22 $45,093 - $57,758	720 Added 16.72%	5,026 $375,000
Q4 2019 Feb 07, 2020	SELL	$61.62 - $67.78 $10,167 - $11,183	-165 Reduced 3.69%	4,306 $279,000
Q3 2019 Nov 08, 2019	BUY	$62.51 - $69.0 $37,193 - $41,055	595 Added 15.35%	4,471 $283,000
Q2 2019 Aug 07, 2019	SELL	$61.87 - $69.38 $25,985 - $29,139	-420 Reduced 9.78%	3,876 $0
Q1 2019 May 07, 2019	SELL	$62.53 - $70.05 $188,590 - $211,270	-3,016 Reduced 41.25%	4,296 $0
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $16,043 - $20,935	-265 Reduced 3.5%	7,312 $457,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $50,965 - $56,427	-715 Reduced 8.62%	7,577 $0
Q2 2018 Aug 06, 2018	SELL	$64.88 - $75.68 $47,816 - $55,776	-737 Reduced 8.16%	8,292 $0
Q1 2018 May 08, 2018	BUY	$72.84 - $88.8 $3,277 - $3,996	45 Added 0.5%	9,029 $0
Q4 2017 Feb 05, 2018	SELL	$71.15 - $83.52 $88,937 - $104,400	-1,250 Reduced 12.21%	8,984 $0
Q3 2017 Nov 06, 2017	BUY	$72.11 - $85.47 $737,973 - $874,699	10,234	10,234 $0

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.1 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.07 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.71 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.56 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adell Harriman & Carpenter Inc, based on Form 13F filings with the SEC.

News

Stay updated on Adell Harriman & Carpenter Inc with notifications on news.

Account